银屑病症状和体征日记的临床意义变化阈值:随机临床试验的二次分析
该研究基于POETYK PSO-1试验中666例中重度斑块状银屑病成人患者数据,将第16周PSSD评分变化锚定PGI-C和PGI-S,识别出15、25、30分三个患者内有意义改善阈值。
要点
- PSSD评分较基线改善≥15分可视为患者感知的有意义变化(锚定PGI-C)。
- 25分改善同时得到PGI-C和PGI-S支持,30分提示更大改善。
- 15、25、30分阈值代表疾病负担逐步减轻,可用于临床试验解读。
核心结论
- PSSD评分改善15、25、30分代表对银屑病患者有意义的疾病负担逐步改善。
研究设计与样本
- 预设分析基于POETYK PSO-1多中心、随机、双盲、安慰剂对照3期试验,纳入666例中重度斑块状银屑病成人患者。
主要发现
- 共666例患者(平均[SD]年龄46.1[13.4]岁;453例男性[68.0%])完成PSSD日记。
- 采用609例分析集识别出三个阈值:较基线改善至少15分(锚定PGI-C)反映患者内有意义变化。
- 25分改善得到PGI-C和PGI-S双重支持,30分变化识别银屑病症状和体征改善更大的患者。
关键数值与推荐
- PSSD评分较基线改善≥15分:锚定PGI-C的患者内有意义变化阈值。
- PSSD评分改善25分:同时得到PGI-C和PGI-S支持的阈值。
- PSSD评分变化30分:识别症状和体征改善更大的患者。
临床怎么用
- 临床解读PSSD评分时,可将15分作为患者感知有意义改善的最低阈值。
- 25分和30分阈值可用于区分改善程度逐步增大的患者亚群。
- 该阈值基于临床试验人群,外推至常规实践需谨慎。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Change from baseline score on the validated Psoriasis Symptoms and Signs Diary (PSSD) is a widely used, patient-reported end point in clinical trials for psoriasis. Meaningful score change thresholds anchored to patient-reported assessments have not been established in a clinical trial setting. OBJECTIVE: To evaluate meaningful within-patient score change thresholds for the PSSD using data from the phase 3 Program to Evaluate the Efficacy and Safety of Deucravacitinib, a Selective TYK2 Inhibitor (POETYK), PSO-1 clinical trial, which compared the efficacy and safety of deucravacitinib vs placebo and apremilast among adults with moderate to severe plaque psoriasis. DESIGN, SETTING, AND PARTICIPANTS: In this predefined analysis using data from the POETYK PSO-1 multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial, conducted from August 7, 2018, to September 2, 2020, 666 adults with moderate to severe plaque psoriasis completed the PSSD daily throughout the trial. Meaningful change thresholds were derived by anchoring mean PSSD score change from baseline to week 16 to category improvements on the Patient Global Impression of Change (PGI-C) and the Patient Global Impression of Severity (PGI-S). INTERVENTIONS: Deucravacitinib, 6 mg, once daily; placebo; or apremilast, 30 mg, twice daily. MAIN OUTCOME AND MEASURES: The main outcome was score change from baseline to week 16 on the PSSD, anchored to the PGI-C and PGI-S. RESULTS: The trial included 666 patients (mean [SD] age, 46.1 [13.4] years; 453 men [68.0%]). Three thresholds were identified using an analysis set of 609 patients. Score improvement of at least 15 points from baseline reflected meaningful within-patient change anchored to the PGI-C. Score improvements of 25 points were supported by both the PGI-C and the PGI-S, while a 30-point score change identified patients with greater improvements in their psoriasis symptoms and signs. CONCLUSIONS AND RELEVANCE: This analysis suggests that PSSD score improvements of 15, 25, or 30 points represent increasing improvements in disease burden that are meaningful to patients with psoriasis.
引用
- Papp KA, Gordon K, Strober B, et al. Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial. JAMA Dermatol. 2024. PMID: 38117487. doi:10.1001/jamadermatol.2023.5058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。